ABN Amro Investment Solutions Lowers Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC

ABN Amro Investment Solutions reduced its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 39.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,197 shares of the company’s stock after selling 9,718 shares during the quarter. ABN Amro Investment Solutions’ holdings in BeOne Medicines were worth $5,178,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ONC. Sequoia Financial Advisors LLC lifted its stake in shares of BeOne Medicines by 4.1% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,281 shares of the company’s stock valued at $436,000 after purchasing an additional 50 shares during the period. Penserra Capital Management LLC raised its position in shares of BeOne Medicines by 2.7% in the third quarter. Penserra Capital Management LLC now owns 2,981 shares of the company’s stock worth $1,015,000 after acquiring an additional 79 shares during the period. Allianz Asset Management GmbH boosted its stake in shares of BeOne Medicines by 3.0% during the 3rd quarter. Allianz Asset Management GmbH now owns 3,400 shares of the company’s stock worth $1,158,000 after acquiring an additional 100 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of BeOne Medicines by 11.7% during the 3rd quarter. Blue Trust Inc. now owns 967 shares of the company’s stock worth $329,000 after acquiring an additional 101 shares in the last quarter. Finally, Anchor Investment Management LLC acquired a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $26,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Insider Activity

In related news, SVP Chan Henry Lee sold 1,660 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total value of $580,203.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Corazon (Corsee) D. Sanders sold 2,627 shares of the business’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $340.90, for a total transaction of $895,544.30. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 105,283 shares of company stock valued at $32,463,041. 6.62% of the stock is currently owned by insiders.

BeOne Medicines Stock Performance

Shares of BeOne Medicines stock opened at $346.07 on Monday. The business’s 50 day moving average price is $329.70 and its 200 day moving average price is $327.17. The company has a market cap of $37.95 billion, a price-to-earnings ratio of 678.57 and a beta of 0.52. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $196.45 and a one year high of $385.22.

Wall Street Analyst Weigh In

Several analysts have commented on ONC shares. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, January 21st. Jefferies Financial Group reiterated a “buy” rating and set a $420.00 target price on shares of BeOne Medicines in a research report on Monday, November 17th. Zacks Research lowered shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 28th. Royal Bank Of Canada reissued an “outperform” rating on shares of BeOne Medicines in a research note on Wednesday, December 17th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $405.00 price target on shares of BeOne Medicines in a research note on Thursday, January 8th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $379.07.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.